The role of raltitrexed/ @entity900 with concurrent radiation therapy in treating XXXX .

@entity1 @entity137 @entity882 @entity5 @entity900 @entity1321 @entity3
OBJECTIVE: To explore the effectiveness and safety of raltitrexed/ @entity900 with concurrent radiotherapy in treating of @entity1 with @entity5 . @entity1 AND METHODS: Sixty-five @entity1 with @entity5 enrolled in this study, received raltitrexed/ @entity900 with concurrent radiotherapy. The treatment consisted of raltitrexed 3 mg/m2 iv 15 min, d1; @entity900 60 mg/m2 iv 60 min, d1, and pelvic radiotherapy, using three-dimensional conformal radiotherapy. The radiotherapy was implemented over Elekta accelerator (Model Type Precise), with 2.0 Gy per fraction for the whole pelvic or pelvic extension field. Central lead shield was used if the dose reached 30 Gy to produce a total dosage of 50 Gy. Following radiation therapies of full pelvic field or extended-field, additional radiation with the dose of 56-60 Gy was administrated to the lymph node @entity3 . Brachytherapy of iridium 192 was completed in our hospital, with the dose of 7Gy per fraction for point A, once a week, with six fractions for internal radiations during the full treatment course of eight weeks. RESULTS: A total of 65 @entity1 completed radiotherapy with two cycles of concurrent chemotherapy. Amongst them, chemotherapy was delayed for a week due to hypoleukocytosis for seven of the @entity1 . Total response rate, three-year disease-free survival, and three-year overall survival OS were 95.4%, 75.4%, and 90.7%. High-grade (>=  3) acute @entity137 were hypoleukocytosis (23.1%) and @entity882 (6.2%) with a prevalence of high-grade (>=  3) late @entity137 at 1.5%. One @entity1 received surgical resection because of a partial @entity1321 after 8 months of radiotherapy. CONCLUSIONS: Raltitrexed/ @entity900 combined with concurrent radiotherapy is effective in treating @entity5 .
